| Date | Time | Source | Headline | Symbol | Company |
| 02/07/2022 | 8:00AM | PR Newswire (US) | KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/25/2022 | 8:00AM | PR Newswire (US) | KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/07/2022 | 8:00AM | PR Newswire (US) | KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/13/2021 | 11:00AM | PR Newswire (US) | KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/13/2021 | 6:14AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/07/2021 | 6:17AM | TipRanks | Analysts’ Top Healthcare Picks: Biohaven Pharmaceutical Holding Co (BHVN), Adicet Bio (ACET) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/04/2021 | 8:00AM | PR Newswire (US) | Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/29/2021 | 8:00AM | PR Newswire (US) | GBM AGILE Opens to Paxalisib in Canada | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/29/2021 | 8:00AM | PR Newswire (Canada) | GBM AGILE Opens to Paxalisib in Canada | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/15/2021 | 11:00AM | PR Newswire (US) | Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/12/2021 | 6:15AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/11/2021 | 8:00AM | PR Newswire (US) | PNOC Study in Childhood Brain Cancer Enrols First Patient | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/10/2021 | 6:09AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/10/2021 | 6:09AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/04/2021 | 8:00AM | PR Newswire (US) | Kazia Enrols First Patient to EVT801 Phase I Clinical Trial | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/04/2021 | 4:00AM | PR Newswire (US) | Kazia Enrols First Patient to EVT801 Phase I Clinical Trial | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 10/29/2021 | 6:09AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 10/07/2021 | 7:14AM | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 10/06/2021 | 10:00AM | PR Newswire (US) | Kazia Therapeutics to Present at LD Micro Main Event | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 09/10/2021 | 12:30PM | PR Newswire (US) | Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 09/01/2021 | 7:25AM | Edgar (US Regulatory) | Securities Registration (foreign Private Issuer) (f-3) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 07/21/2021 | 10:00AM | PR Newswire (US) | Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 06/30/2021 | 10:00AM | PR Newswire (US) | Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 06/15/2021 | 10:00AM | PR Newswire (US) | Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With K... | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 06/07/2021 | 8:00AM | PR Newswire (US) | Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 06/03/2021 | 7:00AM | PR Newswire (US) | Kazia Therapeutics to Present at LD Micro Invitational XI | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 04/19/2021 | 6:11AM | PR Newswire (US) | Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 04/19/2021 | 5:36AM | PR Newswire (US) | Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 04/09/2021 | 6:06AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 03/31/2021 | 6:30AM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:KZIA | Kazia Therapeutics Ltd |